AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16960944 — intervention group
Group type: COMPARATOR
Intervention: Placebo or vehicle
Number of subjects: 4
Study 10321415 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR (150 or 300 mg/d)
Number of subjects: 0
Study 10321415 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR (100, 200, 300, or 400 mg/d)
Number of subjects: 0
Study 10321415 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR (50 to 150 or 100 to 300 mg/d)
Number of subjects: 0
Study 10321415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10321415 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 0
Study 8562960 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF (300 micrograms subcutaneously)
Number of subjects: 20
Study 8562960 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 20
Study 1992393 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10‐30 mg sublingually, then 40‐120 mg/day orally)
Number of subjects: 49
Study 1992393 — intervention group
Group type: COMPARATOR
Intervention: Hydralazine (6.25‐12.5 mg intravenously, then 80‐120 mg/day orally)
Number of subjects: 49
Study 1992393 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 49
Study 1992393 — intervention group
Group type: COMPARATOR
Intervention: Hydralazine
Number of subjects: 49
Study 6351332 — intervention group
Group type: EXPERIMENTAL
Intervention: Negatively ionised air (4 X 10(5) ‐ 10 X 10(5) ions/cm3)
Number of subjects: 11
Study 6351332 — intervention group
Group type: COMPARATOR
Intervention: Control room air
Number of subjects: 11
Study 6351332 — intervention group
Group type: EXPERIMENTAL
Intervention: Negatively ionised air
Number of subjects: 11
Study 6351332 — intervention group
Group type: COMPARATOR
Intervention: Control challenge
Number of subjects: 11
Study 31444617 — intervention group
Group type: EXPERIMENTAL
Intervention: Fedratinib (200 mg and above)
Number of subjects: 452
Study 30024999 — intervention group
Group type: EXPERIMENTAL
Intervention: PDT1 (660 nm, 100 mW, 60 seconds) with toluidine blue
Number of subjects: 72
Study 30024999 — intervention group
Group type: EXPERIMENTAL
Intervention: PDT2 (660 nm, 100 mW, 60 seconds) with phenothiazine chloride dye
Number of subjects: 72
Study 30024999 — intervention group
Group type: EXPERIMENTAL
Intervention: LAD (light-emitting diode with toluidine blue)
Number of subjects: 72
Study 30024999 — intervention group
Group type: EXPERIMENTAL
Intervention: Toluidine blue (60 seconds)
Number of subjects: 72
Study 30024999 — intervention group
Group type: COMPARATOR
Intervention: 0.2% chlorhexidine-based solution (positive control)
Number of subjects: 72
Study 30024999 — intervention group
Group type: COMPARATOR
Intervention: No treatment (negative control)
Number of subjects: 72
Study 27210275 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprostene bunod (LBN) 0.024% QD
Number of subjects: 387
Study 27210275 — intervention group
Group type: COMPARATOR
Intervention: Timolol maleate 0.5% BID
Number of subjects: 387
Study 24750904 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone at a dose of 2 g, given every 24 hours intravenously for four days, in addition to stroke-unit care
Number of subjects: 2470
Study 24750904 — intervention group
Group type: COMPARATOR
Intervention: Standard stroke-unit care without preventive antibiotic therapy
Number of subjects: 2470
Study 21700408 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-guided pulmonary radiofrequency ablation (RFA)
Number of subjects: 480
Study 21700408 — intervention group
Group type: COMPARATOR
Intervention: Surgical resection of pulmonary metastases
Number of subjects: 480
Study 21700408 — intervention group
Group type: EXPERIMENTAL
Intervention: RFA treatment
Number of subjects: 480
Study 21700408 — intervention group
Group type: EXPERIMENTAL
Intervention: All NPC patients with pulmonary metastases
Number of subjects: 480
Study 20483826 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive meditation training (approximately 5 hr/day for 3 months)
Number of subjects: 60
Study 20483826 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group (no training during the initial phase)
Number of subjects: 60
Study 17346705 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical capsaicin applied at and just above the level of spinal cord injury
Number of subjects: 30
Study 17346705 — intervention group
Group type: EXPERIMENTAL
Intervention: Touch stimuli applied at injury level
Number of subjects: 30
Study 17346705 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive punctuate stimuli applied above and at injury level
Number of subjects: 30
Study 16259624 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy (supervised sessions three times per week for eight weeks)
Number of subjects: 90
Study 16259624 — intervention group
Group type: COMPARATOR
Intervention: Attention-control intervention (body-conditioning exercises and games without aerobic activity, three times per week for eight weeks)
Number of subjects: 90
Study 16259624 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 90
Study 12177109 — intervention group
Group type: EXPERIMENTAL
Intervention: GSH (1,500 mg/m(2) over a 15-minute infusion before oxaliplatin)
Number of subjects: 52
Study 12177109 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline solution)
Number of subjects: 52
Study 9934732 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 100 microg s.c.
Number of subjects: 12
Study 9934732 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 12
Study 7760093 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg propofol
Number of subjects: 60
Study 7760093 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg methohexital
Number of subjects: 60
Study 7760093 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg thiopental
Number of subjects: 60
Study 7760093 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg etomidate
Number of subjects: 60
Study 7760093 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 micrograms/kg fentanyl and 0.15 mg/kg midazolam
Number of subjects: 60
Study 7760093 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg ketamine and 0.15 mg/kg midazolam
Number of subjects: 60
Study 7760093 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal intubation (after all interventions)
Number of subjects: 60
Study 31663647 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudo-observation (PO) approach
Number of subjects: 0
Study 31663647 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-imputation (MI) approach
Number of subjects: 0
Study 31663647 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin treatment
Number of subjects: 0
Study 31661942 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography group (UG)
Number of subjects: 147
Study 31661942 — intervention group
Group type: COMPARATOR
Intervention: Conventional group (CG)
Number of subjects: 147
Study 31661942 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 147
Study 27903809 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimanual ovarian palpation
Number of subjects: 20872
Study 27903809 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimanual ovarian palpation with other screening tests
Number of subjects: 20872
Study 25845680 — intervention group
Group type: EXPERIMENTAL
Intervention: AAF with synbiotics (oligofructose, long-chain inulin, acidic oligosaccharides, Bifidobacterium breve M-16V)
Number of subjects: 110
Study 25845680 — intervention group
Group type: COMPARATOR
Intervention: AAF (control)
Number of subjects: 110
Study 23380426 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg twice daily for 9 days
Number of subjects: 23
Study 23380426 — intervention group
Group type: COMPARATOR
Intervention: Tolbutamide 500 mg single dose on Day 5
Number of subjects: 23
Study 20880269 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa-selegiline
Number of subjects: 52
Study 20880269 — intervention group
Group type: COMPARATOR
Intervention: levodopa
Number of subjects: 52
Study 18628104 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive algorithms for scheduling tasks
Number of subjects: 48
Study 18628104 — intervention group
Group type: COMPARATOR
Intervention: Random scheduling of tasks
Number of subjects: 48
Study 16131700 — intervention group
Group type: EXPERIMENTAL
Intervention: HGI evening meal
Number of subjects: 7
Study 16131700 — intervention group
Group type: COMPARATOR
Intervention: LGI evening meal
Number of subjects: 7
Study 12477674 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 FiO2 in air
Number of subjects: 27
Study 12477674 — intervention group
Group type: COMPARATOR
Intervention: 0.4 FiO2 in N2O
Number of subjects: 27
Study 12477674 — intervention group
Group type: COMPARATOR
Intervention: 100% O2
Number of subjects: 27
Study 10575404 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycobacterium w vaccine
Number of subjects: 157
Study 10575404 — intervention group
Group type: COMPARATOR
Intervention: MDT alone (placebo)
Number of subjects: 157
Study 8707534 — intervention group
Group type: EXPERIMENTAL
Intervention: Bereavement Group Postvention (BGP)
Number of subjects: 0
Study 8707534 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Group Postvention (SGP)
Number of subjects: 0
Study 8707534 — intervention group
Group type: COMPARATOR
Intervention: Both groups (BGP and SGP)
Number of subjects: 0
Study 1672569 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteinising-hormone releasing-hormone (LH-RH), 1.2 mg daily intranasally for four weeks
Number of subjects: 118
Study 1672569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 6555015 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefonicid (1 g intramuscularly)
Number of subjects: 50
Study 6555015 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin (500 mg orally three times a day for 7 days)
Number of subjects: 50
Study 30703077 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant zoster vaccine (RZV; Shingrix)
Number of subjects: 6773
Study 29359603 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher parental education level
Number of subjects: 40
Study 29359603 — intervention group
Group type: COMPARATOR
Intervention: Low parental education level
Number of subjects: 40
Study 29359603 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall parental education level
Number of subjects: 40
Study 26563608 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine continuous infusion (group R)
Number of subjects: 60
Study 26563608 — intervention group
Group type: COMPARATOR
Intervention: Saline continuous infusion (placebo, group P)
Number of subjects: 60
Study 24831421 — intervention group
Group type: EXPERIMENTAL
Intervention: Active medication (gabapentin or pregabalin)
Number of subjects: 12
Study 24831421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 21898137 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) 20 mg/kg IV over 15 min
Number of subjects: 79
Study 21898137 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam (LOR) 0.1 mg/kg IV over 2-4 min
Number of subjects: 79
Study 19713172 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g/d seaweed (Undaria pinnatifida)
Number of subjects: 27
Study 19713172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 19713172 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g/d seaweed
Number of subjects: 27
Study 19713172 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g/d seaweed
Number of subjects: 27
Study 18549664 — intervention group
Group type: EXPERIMENTAL
Intervention: Doripenem 500 mg every 8 h by a 1-h intravenous infusion
Number of subjects: 448
Study 18549664 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin/tazobactam 4.5 g every 6 h by 30-min IV infusion
Number of subjects: 448
Study 16148021 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-dense sequential chemotherapy with epirubicin (110 mg/m2) followed by paclitaxel (250 mg/m2) and intensified CMF (cyclophosphamide 840 mg/m2, methotrexate 47 mg/m2, fluorouracil 840 mg/m2)
Number of subjects: 595
Study 16148021 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving four cycles of epirubicin followed by four cycles of CMF
Number of subjects: 595
Study 16148021 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-dense sequential chemotherapy with epirubicin followed by paclitaxel and intensified CMF
Number of subjects: 595
Study 16148021 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 595
Study 12369047 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodiafiltration (HDF)
Number of subjects: 12
Study 12369047 — intervention group
Group type: COMPARATOR
Intervention: Standard hemodialysis (HD)
Number of subjects: 12
Study 9931521 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 137
Study 9931521 — intervention group
Group type: EXPERIMENTAL
Intervention: Eligible NR group
Number of subjects: 137
Study 8850378 — intervention group
Group type: EXPERIMENTAL
Intervention: L-propionylcarnitine 500 mg tid for 6 weeks
Number of subjects: 74
Study 8850378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 2211201 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modality therapy (consolidation radiotherapy after induction chemotherapy)
Number of subjects: 154
Study 2211201 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 154
Study 2211201 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modality therapy
Number of subjects: 154
Study 2211201 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 154
Study 374163 — intervention group
Group type: EXPERIMENTAL
Intervention: Two 225 mg tablets of Phyllocontin (slow-release aminophylline)
Number of subjects: 12
Study 374163 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 12
Study 31256724 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control (target systolic BP <120 mm Hg)
Number of subjects: 337
Study 31256724 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure control (target systolic BP <140 mm Hg)
Number of subjects: 337
Study 31256724 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control
Number of subjects: 337
Study 31256724 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure control
Number of subjects: 337
Study 29790477 — intervention group
Group type: EXPERIMENTAL
Intervention: Biolimus A9-coated stent (BA9-DCS)
Number of subjects: 667
Study 27052634 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (100 mg three times a day)
Number of subjects: 108
Study 27052634 — intervention group
Group type: COMPARATOR
Intervention: Metformin (1.5 g/day)
Number of subjects: 108
Study 23412262 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral approach
Number of subjects: 47
Study 23412262 — intervention group
Group type: COMPARATOR
Intervention: Medial approach
Number of subjects: 47
Study 23412262 — intervention group
Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 47
Study 23207850 — intervention group
Group type: EXPERIMENTAL
Intervention: LED-800 (800 mW/cm²) + immediate light activation (t0)
Number of subjects: 60
Study 23207850 — intervention group
Group type: EXPERIMENTAL
Intervention: LED-1500 (1500 mW/cm²) + immediate light activation (t0)
Number of subjects: 60
Study 23207850 — intervention group
Group type: COMPARATOR
Intervention: QTH (600 mW/cm²) + immediate light activation (t0)
Number of subjects: 60
Study 23207850 — intervention group
Group type: EXPERIMENTAL
Intervention: LED-800 + light activation after 10 min (t10)
Number of subjects: 60
Study 23207850 — intervention group
Group type: EXPERIMENTAL
Intervention: LED-1500 + light activation after 10 min (t10)
Number of subjects: 60
Study 23207850 — intervention group
Group type: COMPARATOR
Intervention: QTH + light activation after 10 min (t10)
Number of subjects: 60
Study 21152050 — intervention group
Group type: EXPERIMENTAL
Intervention: Snake photos displaying typical striking posture
Number of subjects: 74
Study 21152050 — intervention group
Group type: COMPARATOR
Intervention: Snake photos displaying resting posture
Number of subjects: 74
Study 18056903 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin plus GP IIb/IIIa inhibitors (n = 4603)
Number of subjects: 13819
Study 18056903 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin plus GP IIb/IIIa inhibitors (n = 4604)
Number of subjects: 13819
Study 18056903 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin monotherapy (n = 4612)
Number of subjects: 13819
Study 18056903 — intervention group
Group type: COMPARATOR
Intervention: Deferred use of GP IIb/IIIa inhibitors
Number of subjects: 13819
Study 15618549 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (FF)
Number of subjects: 0
Study 15618549 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil (GF)
Number of subjects: 0
Study 11817923 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education intervention (eight lectures on the health consequences of smoking)
Number of subjects: 155
Study 11817923 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 155
Study 10609041 — intervention group
Group type: EXPERIMENTAL
Intervention: PPMV (Positive Pressure Mask Ventilation)
Number of subjects: 669
Study 10609041 — intervention group
Group type: COMPARATOR
Intervention: No PPMV
Number of subjects: 669
Study 10609041 — intervention group
Group type: EXPERIMENTAL
Intervention: PPMV
Number of subjects: 669
Study 10609041 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical qualification of anesthesiologists
Number of subjects: 669
Study 7744539 — intervention group
Group type: EXPERIMENTAL
Intervention: Moricizine HCl at 200 mg twice daily for 5 days
Number of subjects: 21
Study 7744539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 2202510 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime (2 gm every 12 hours)
Number of subjects: 100
Study 2202510 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin (2 gm every six hours)
Number of subjects: 100
Study 6216612 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous procaine penicillin G (4.8 x 10(6) units plus 1 g of oral probenecid)
Number of subjects: 247
Study 6216612 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectinomycin (2 g)
Number of subjects: 247
Study 31990877 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS group (received SMS about bowel preparation practices 3 days before colonoscopy)
Number of subjects: 200
Study 31990877 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS group
Number of subjects: 200
Study 31990877 — intervention group
Group type: COMPARATOR
Intervention: No-SMS group
Number of subjects: 200
Study 28624398 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote zone native T1 values (>1,129 ms)
Number of subjects: 255
Study 28624398 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote zone native T1
Number of subjects: 255
Study 28624398 — intervention group
Group type: EXPERIMENTAL
Intervention: Native T1 of remote myocardium
Number of subjects: 255
Study 28624398 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of remote zone native T1 to a model of prognostic CMR parameters
Number of subjects: 255
Study 27306734 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein egg-based breakfast (30g protein)
Number of subjects: 48
Study 27306734 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate protein egg-based breakfast (20g protein + 7g fiber)
Number of subjects: 48
Study 27306734 — intervention group
Group type: COMPARATOR
Intervention: Low protein cereal breakfast (10g protein)
Number of subjects: 48
Study 24596910 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon plasma cleaning for 375 seconds with ceramic liner (Subgroup A)
Number of subjects: 90
Study 24596910 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon plasma cleaning for 375 seconds without ceramic liner (Subgroup B)
Number of subjects: 90
Study 24596910 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon plasma cleaning for 750 seconds with ceramic liner (Subgroup A)
Number of subjects: 90
Study 24596910 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon plasma cleaning for 750 seconds without ceramic liner (Subgroup B)
Number of subjects: 90
Study 24596910 — intervention group
Group type: EXPERIMENTAL
Intervention: Steam cleaning with ceramic liner (Subgroup A)
Number of subjects: 90
Study 24596910 — intervention group
Group type: EXPERIMENTAL
Intervention: Steam cleaning without ceramic liner (Subgroup B)
Number of subjects: 90
Study 19740611 — intervention group
Group type: EXPERIMENTAL
Intervention: Underage drinking behaviors in communities
Number of subjects: 18730
Study 19740611 — intervention group
Group type: EXPERIMENTAL
Intervention: Community context factors
Number of subjects: 18730
Study 18640632 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy treatment, details on dosage and duration not specified.
Number of subjects: 0
Study 18640632 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative study on aromatherapists' experiences, no specific intervention details provided.
Number of subjects: 0
Study 16820213 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 20
Study 16820213 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 20
Study 12816787 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytate-reduced MCD and phytate-reduced porridge (PR group)
Number of subjects: 300
Study 12816787 — intervention group
Group type: COMPARATOR
Intervention: Commercial milk-based cereal drink (MCD) and porridge (CC group)
Number of subjects: 300
Study 12816787 — intervention group
Group type: COMPARATOR
Intervention: Milk-based infant formula and porridge with the usual phytate content (IF group)
Number of subjects: 300
Study 11182958 — intervention group
Group type: EXPERIMENTAL
Intervention: CQI intervention
Number of subjects: 6830
Study 11182958 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 6830
Study 8773813 — intervention group
Group type: EXPERIMENTAL
Intervention: One session of education
Number of subjects: 64
Study 8773813 — intervention group
Group type: EXPERIMENTAL
Intervention: Three sessions of education
Number of subjects: 64
Study 8773813 — intervention group
Group type: COMPARATOR
Intervention: Control group (none)
Number of subjects: 64